spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Kissei Pharmaceutical 

 HSMN NewsFeed - 4 Aug 2022
Amgen to Acquire Chemocentryx for $4 Billion in Cash
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 23 Nov 2015
ObsEva Closes CHF 60 (USD 60) Million in Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 19 Jun 2013
Actavis And Kissei File Lawsuits Against Sandoz And Hetero For Infringement Of Rapaflo(R) Patent
Biopharmaceuticals Urology Generics Litigation
 HSMN NewsFeed - 7 May 2010
Recordati Signs an Agreement With Zambon for the Co-Marketing of Silodosin in France
Biopharmaceuticals Urology Licensing
 HSMN NewsFeed - 3 Feb 2010
Silodosin (Urorec(R)/Silodyx) Approved by the European Commission for the Treatment of the Signs and Symptoms of BPH (Benign Prostatic Hyperplasia)
Biopharmaceuticals Urology Regulatory
 HSMN NewsFeed - 9 Dec 2009
New Published Data Demonstrate Long-Term Safety, Efficacy and Tolerability of Watson's RAPAFLO(R) (silodosin) for Benign Prostatic Hyperplasia (BPH) Symptom Relief
Biopharmaceuticals Urology
 HSMN NewsFeed - 3 Aug 2009
NovaBay(R) Pharmaceuticals Names Roy J. Wu as Senior Vice President for Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 May 2009
RAPAFLO(TM) (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Days
Biopharmaceuticals Urology
 HSMN NewsFeed - 22 Apr 2009
MediciNova Reports Final Data from Phase II MN-221 Emergency Department Clinical Trial (MN-221-CL-006); Hospitalization Rates Decrease 45 Percent With MN-221 Plus Standardized Care in Asthma Patients
Biopharmaceuticals
 HSMN NewsFeed - 7 Apr 2009
Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
Biopharmaceuticals Urology
 HSMN NewsFeed - 8 Oct 2008
Watson Receives US FDA Approval for RAPAFLO(TM) (silodosin) for the Treatment of Benign Prostatic Hyperplasia (BPH)
Biopharmaceuticals FDA Urology
 HSMN NewsFeed - 21 May 2008
Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
Biopharmaceuticals Urology
 HSMN NewsFeed - 16 Jan 2007
Watson Announces Positive Phase 3 Study Results on Silodosin for Treatment of Benign Prostatic Hyperplasia
Biopharmaceuticals Urology
Return to NewsFeed  

 Additional items found! 7

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 7 additional stories matching:
Kissei Pharmaceutical
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.